Recombinant human erythropoietin as a neuroprotective therapy in brain ischemia;La eritropoyetina humana recombinante como terapia para la neuroprotección en la isquemia cerebral

Biotecnologia Aplicada

Volumn 25, Issue 3, 2008, Pages 216-229

  Sosa, Iliana ^a   Mengana, Yuneidys ^a   García, Jorge D ^b   Subiros, Nelvis ^b   Cruz, Janette ^c   Muñoz, Adriana ^d   Nuñez, Yanier ^d   García, Julio C ^a  

^a Centro Nacional de Producción de Animales de Laboratorio CENPALAB   (Cuba)

^b INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA   (Cuba)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^d CENTRO DE INVESTIGACIÓN Y DESARROLLO DE MEDICAMENTOS CIDEM   (Cuba)

Author keywords

Brain ischemia; Erythropoietin; Intranasal; Neuroprotection

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; SIALIC ACID;

BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHROPOIESIS; HUMAN; NERVE CELL; NEUROPROTECTION; NONHUMAN; REVIEW;

RODENTIA;

EID: 76749115236     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Anuario Estadístico de Salud en Cuba. [Ref Type: Electronic Citation]. Disponible en: http://www.infomed.sld.cu/servicios/estadisticas/; 2003.
2. Hill MD, Hachinski V. Stroke treatment: Time is brain. Lancet 1998;352(3): SIII10-4.
3. Lainez JM, Santonja JM. Historia natural de la enfermedad vascular cerebral. En: JR Prous, ed. Manual de enfermedades vasculares cerebrales 1999:55.
4. Miranda QJA. Enfermedades cerebrovasculares. Editorial Oriente, Santiago de Cuba; 2004.
5. Guevara GM, Rodríguez R, Álvarez LA, Riaño MA, Rodríguez P. Mecanismos celulares y moleculares de la enfermedad cerebrovascular isquémica. Rev Cubana Med 2004;43(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci-arttext&pid=S0034-75232004000400- 008&lng=es&nrm=iso.
6. Rodríguez ML, Galvizu SR, Álvarez GE. Neuromodulació n farmacológica en la enfermedad cerebrovascular. Temas actualizados. Rev Cubana Med 2002;41: 34-9.
7. Krieglstein J, Klump S. Pharmacology of cerebral ischemia. Rev Mex 2002; 3(3):179.
8. Hacke W. Neuroprotective Strategies for Early Intervention in Acute Ischaemic Stroke. Cerebrovascular Diseases 1997, Vol. 7 Suppl 2.
9. Buergo Zuaznábar MA, Fernández-Concepción O, Pérez Nellar J, Pando Cabrera A. Guías de práctica clínica para las enfermedades cerebrovasculares. Medisur 2007 (Número Especial):1-25. Disponible en: http://medisur.sld.cu/index.php/ medisur/article/view/246/730.
10. García Salman JD. Protección neuronal endógena: un enfoque alternativo. Rev Neurol 2004;38:150-5.
11. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 2003;26: 248-54.
12. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971-5.
13. Weiss MJ. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist 2003;8(3):18-29.
14. Sakanaka M, Wen T-C, Matsuda S, Seiji Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci PNAS 1998;95:4635-40.
15. Marti HH, Gassmann M, Wenger RH, Kvietikova I, Morganti-Kossmann MC, Kossmann T, et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997;51:416-8.
16. Van der Meer P, Voors A, Lipsic E, Van Meer G, Dirk J, Van Veldhuisen D. Erythropoietin in cardiovascular diseases. Eur Heart J 2004;25:285-91.
17. Vital M. Accidente cerebrovascular: esperanza en la investigación; 1999. Ref Type: Internet Communication
18. Castillo J, Martí-Vilalta JL, Martínez-Vila E, Matías-Guiu J. Manual de enfermedades vasculares cerebrales. Barcelona, España; 1999:388.
19. Villa P, van BJ, Larsen AK, Gerwien J, Christensen S, Cerami A, et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007;27:552-63.
20. Castillo J. Luces y sombras de la neuroprotección en la isquemia cerebral. Formación continuada para farmacéuticos de hospitales [4], 95-121. 2002. Universidad de Santiago de Compostela, Santiago de Compostela, España [Ref Type: Conference Proceeding].
21. Kwakkel G, Kollen B, Lindeman E. Understanding the pattern of functional recovery after stroke: Facts and theories. Restor Neurol Neurosci 2004;22:281-99.
22. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004;1:36-45.
23. Castillo J, Rodríguez I. Biochemical changes and inflammatory response as markers for brain ischaemia: Molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004;17:7-18.
24. Secades JJ, Varez-Sabin J, Rubio F, Lozano R, Davalos A, Castillo J. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis 2006;21:380-5.
25. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006;26: 1465-78.
26. Muir KW. Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness. CNS Drugs 2001;15:921-30.
27. Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of Stroke: Lessons from animal models. Metab Brain Dis 2004; 19:151-67.
28. Fisher M. The ischemic penumbra-identification, evolution and treatment concepts. Cerebrovasc Dis 2004;17(1):1-6.
29. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995;92: 3717-20.
30. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43: 649-59.
31. Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997;378:609-16.
32. Gassmann M, Heinicke K, Soliz J, Ogunshola O. Non-erythroid functions of erythropoietin. In: Roach RC, ed. Hypoxia: Through the lifecycle. Kluwer Academic/Plenum Publishers, New York, 2003:1-8.
33. Kalialis LV, Olsen NV. Erythropoietina new therapy in cerebral ischemia¿ Ugeskr Laeger 2003;165:2477-81.
34. Eid T, Brines M. Recombinant human erythropoietin for neuroprotection: what is the evidence¿ Clin Breast Cancer 2002; Suppl 3:S109-15.
35. Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol 2004;207: 3233-42.
36. Lipšic E, Schoemaker RG, Van der Meer P, Voors AA, Van Veldhuisen D, Van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-7.
37. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, Mackenzie ET et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19: 643-51.
38. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996;8:666-76.
39. Juul SE, Anderson D, Li Y. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998;43:40-9.
40. Siren AL, Ehrenreich H. Erythropoietin-a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251:179-84.
41. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42.
42. Catania MA, Marciano MC, Parisi A, Sturiale A, Buemi M, Grasso G, et al. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur J Pharmacol 2002;437:147-50.
43. Belayev L, Khoutorova L, Zhao W, Vigdorchik A, Belayev A, Busto R, et al. Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke 2005;36: 1071-6.
44. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044-9.
45. Catania MA, Crupi A, Firenzuoli F, Parisi A, Sturiale A, Squadrito F, et al. Oral administration of a soy extract improves endothelial dysfunction in ovariectomized rats. Planta Med 2002;68:1142-4.
46. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000;401:349-56.
47. Chattopadhyay A, Choudhury TD, Bandyopadhyay D, Datta AG. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 2000;59:419-25.
48. Olsen N.V. Central nervous system frontiers for the use of erythropoietin. Clin Infect Dis 2003;37:323.
49. Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of erythopoietin alfa. Nephrol Dial Transplant 2002; 17(1):8-17.
50. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxicischemic brain damage. Acta Paediatr Suppl 2002;91:36-42.
51. Chong ZZ, Kang J, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-9.
52. Siren AL, Knerlich F, Schilling L, Kamrowski-Kruck H, Hahn A, Ehrenreich H. Differential glial and vascular expression of endothelins and their receptors in rat brain after neurotrauma. Neurochem Res 2000; 25:957-69.
53. Agnello D, Bigini P, Villa P, Mennini T, Ceremi A, Brines M, et al. Erythropoietin exerts anti-inflammatory effect on the center nerves system in the model of experimental autoinmune encephalomyelitis. Brain Res 2002; 952:128-34.
54. Diaz Z, Assaraf MI, Miller WH Jr, Schipper HM. Astroglial citoprotection by erythopoietin pre-conditioning: implications for isquemic and degenerative CNS disorders. J Neurochem 2005;93:392-402.
55. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005;387:5-10.
56. Becerra SP, Amaral J. Erythropoietin-an endogenous retinal survival factor. Engl J Med 2002;347:1968-70.
57. Kitagawa K, Matsumoto M, Matsushita K, Mandai K, Mabuchi T, Yanagihara T, et al. Ischemic tolerance in moderately symptomatic gerbils after unilateral carotid occlusion. Brain Res 1996;716:39-46.
58. Solaroglu I, Solaroglu A, Kaptanoglu E, Dede S, Haberal A, Beskonakli E, et al. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst 2003;19:19-22.
59. Grasso G. Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage. J Neurosurg Sci 2001;45:7-14.
60. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005;6:484-94.
61. Zangheri EO, Suárez JR, Fernández FO, Campana H, Silva JC, Ponce FE. Erythropoietic action of tissue extracts. Nature 1962;194: 929-38.
62. Chabrier PE, Merle-Pallardy C, Auguet M. Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Cell Mol Life Sci 1999;55:1029-35.
63. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76:105-16.
64. Martínez-Estrada OM, Rodríguez-Millan E, González D, Vicente E. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003;18:2538-44.
65. Cerami A. Beyond erythropoiesis: novel application for recombinant human erythropoietin. Semin Hematol 2001;38:33-9.
66. Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999;2:148-58.
67. Arango-Dávila C, Escobar-Betancourt M, Cardona-Gómez GP, Pimienta-Jiménez H. Fisiopatología de la isquemia cerebral focal: aspectos básicos y proyección a la clínica. Rev Neurol 2004;39(2):156-65.
68. Nagai A, Nakagawa E, Choi HB. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001;60:386-92.
69. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002;22:10291-301.
70. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
71. Siren AL, Knerlich F, Poser W. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001;101:271-6.
72. Eid T, Brines ML, Cerami A, Spencer DD, Kim JH, Schweitzer JS, et al. Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis. J Neuropathol Exp Neurol 2004;63:73-83.
73. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004; 19:195-206.
74. Alafaci C, Salpietro F, Grasso G, Sfacteria A, Passalacqua M, Morabito A, et al. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 2000;406:219-25.
75. Sinn D, Chu K, Lee S. Erythropoietin has neuroprotective effects with functional recovery in experimental intracerebral hemorrhage. Disponible en: http://www. abstracts2view. com/aan. 57th Annual Meeting of the American Academy of Neurology. 2005. Ref Type: Internet Communication.
76. Lu D, Mahmood A, Qu C. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma 2005;22:1011-7.
77. atsiv I, Grigoriadis N, Simeonidou C. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 2005;19:1701-3.
78. Celik M, Gokmen N, Erbayraktar S. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002;99:2258-63.
79. Gorio A, Madaschi L, Di SB, Carelli S, Di Giulio AM, De BS, et al. Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci USA 2005;102:16379-84.
80. Sattler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bahr M, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11(2):S181-92.
81. Diem R, Sattler MB, Merkler D, Demmer I, Maier K, Stadelmann C, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005;128:375-85.
82. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004;101:823-8.
83. Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004; 9:42-54.
84. Sola A, Rogido M, Lee BH, Genetta T, Wen TC. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res 2005;57:481-7.
85. Kumral A, Ozer E, Yilmaz O, Akhisaroglu M, Gokmen N, Duman N, et al. Neuroprotective effect of erythropoietin on hypoxicischemic brain injury in neonatal rats. Biol Neonate 2003;83:224-8.
86. Chang Y, Mu D, Wendland M. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res 2005;58:106-11.
87. Bohlius J, Langensiepen S, Schwarzer G. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98.
88. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001;21:9733-43.
89. Fisher M. El objetivo del tratamiento en la enfermedad cerebrovascular aguda y los enfoques terapéuticos neuroprotectores. Rev Neurol 1999;29:536-44.
90. Hossmann KA. Pathophysiology and Therapy of Experimental Stroke. Cell Mol Neurobiol 2006;26:1057-83.
91. Ginsberg C, Busto R. Rodent models of ce-rebral ischemia. Stroke 1989;20:1627-42.
92. Traysman RJ. Animals models of focal and global cerebral ischaemia. ILAR J 2003;44:85-95.
93. Sosa I, García Salman JD. Isquemia cerebral y neuroprotección. Disponible en: www.monografias.com\trabajos45\ isquemiacerebral\isquemia-cerebral.shtml. 2007. Ref Type: Internet Communication.
94. Ehrenreich H, Siren AL. Erythropoietin for Treatment of Human Brain Disease: Experience from Proof-of-Concept Trials. In: Springer US, ed. Erythropoietin and the Nervous System. 2006.
95. Rogalewski A, Schneider A, Ringelstein EB, Schäbitz WR. Toward a Multimodal Neuroprotective Treatment of Stroke. Stroke 2006;37:1129-36.
96. Torup L, Leist M. Development of Non-Erythropoietic Erythropoietin Variants for Neuroprotection. In: Springer US, ed. Erythropoietin and the Nervous System. 2006.
97. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003;100:6741-6.
98. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005;102:2046-51.
99. Weber A, Maier RF, Hoffmann U, Grips M, Hoppenz M, Aktas AG, et al. Erythropoietin improves synaptic transmission during and following ischemia in rat hippocampal slice cultures. Brain Res 2002;958:305-11.
100. Hilger PA. Applied anatomy and physiology of the nose. En: Adams GL, Boies LR, Hilger PA, eds. Boies Fundamentals of Otolaryngology. Philadelphia: WB Saunders; 1989.
101. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003;87:187-98.
102. Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001;187:91-7.
103. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002;7:1184-9.
104. Banks AW. Are the extracellular pathways a conduit for the delivery of therapeutics to the brain¿ Curr Pharm Des 2004;10:1365-70.
105. Sosa I, García Rodríguez JC, Santana J, Subiros N, González C, Rodríguez Y, et al. Intranasal administration of recombinant human Erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. Pharmacologyonline 2006;1: 100-12.
106. Sosa I, Cruz J, Santana J, Mengana Y, García JD, Ozuna GT, et al. Paso de la molécula de eritropoyetina humana recombinante con bajo contenido de ácido siálico al sistema nervioso central por la vía intranasal en los modelos del meriones unguiculatus y el pri-mate no humano Macaca fascicularis. Rev Salud Anim 2007;29:1-6.
107. Sosa TI, García Salman JD. Neuroprotección en la isquemia cerebral. Experiencias con la eritropoyetina humana recombinante. Rev Ecuat Neurol 2007;16(2). Disponible en http://www.medicosecuador.com/revecuatneurol/ vol16-n2-2007/articulos-revision/neuroprotecciona.htm.
108. o Congreso Virtual Hispanoamericano de Anatomía Patológica; 2005. [Ref Type: Electronic Citation].
109. Bacardí DM, Cosme K, Porras DN, Rodríguez. Criterios preclínicos que sustentan el uso de la eritropoyetina recombinante humana. Biotecnol Apl 2005;22:173-7.
110. Muñoz Cernuda A, León Rodríguez R, García Rodríguez JC, Nuñez Figueredo Y, Pardo Ruiz Z, García Salman JD, et al. Formulaciones nasales de EPOhr con bajo contenido de ácido siálico para el tratamiento de enfermedades del sistema nervioso central. [20050138]. 22-7-2005. Cuba [Ref Type: Patent].
111. Maggio ET. Recent developments in intranasal drug delivery technology are creating new vistas for peptide and protein therapeutics. Expert Opin Drug Deliv 2005;3(4): 529-39.